Exact Sciences Corp
NASDAQ:EXAS
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
41.33
75.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Exact Sciences Corp
Exact Sciences Corp
Accrued Liabilities
Exact Sciences Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Accrued Liabilities
$341.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
20%
|
CAGR 10-Years
41%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
Exact Sciences Corp
Glance View
Exact Sciences Corp. is a pioneering diagnostics company that focuses on the early detection and prevention of colorectal cancer, which is one of the deadliest cancers in the world. Founded in 1995 and based in Madison, Wisconsin, Exact Sciences made significant strides with its flagship product, Cologuard, the first non-invasive stool-based DNA test approved by the FDA for colorectal cancer screening. By combining advanced molecular biology and genetic testing, the company aims to enhance the efficiency and effectiveness of cancer screening processes, ultimately saving lives and reducing healthcare costs. This innovation has positioned Exact Sciences as a leader in preventive healthcare, catering to the growing demand for accessible and reliable cancer screening solutions in the U.S. and beyond. As the company expands its product portfolio, it is also actively working on additional tests to detect other types of cancers and diseases, demonstrating its commitment to broadening its impact in the health sector. Exact Sciences has engaged in strategic collaborations and acquisitions to accelerate growth and innovation, including partnerships with large biopharmaceutical companies and healthcare providers. For investors, Exact Sciences presents a compelling opportunity—a company at the forefront of a vital healthcare sector, with proven products, a robust pipeline, and a mission that resonates with the increasing emphasis on preventive medicine. With strong revenue growth and a dedicated focus on research and development, Exact Sciences is poised for a future where early intervention and personalized care become the norm.
See Also
What is Exact Sciences Corp's Accrued Liabilities?
Accrued Liabilities
341.2m
USD
Based on the financial report for Sep 30, 2024, Exact Sciences Corp's Accrued Liabilities amounts to 341.2m USD.
What is Exact Sciences Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
41%
Over the last year, the Accrued Liabilities growth was 0%. The average annual Accrued Liabilities growth rates for Exact Sciences Corp have been 2% over the past three years , 20% over the past five years , and 41% over the past ten years .
You don't have any saved screeners yet
